Resource Utilization With Insulin Pump Therapy for Type 2 Diabetes Mellitus
Published Online: December 21, 2010
Peter M. Lynch, MPH; Aylin Altan Riedel, PhD; Navendu Samant, MS; Ying Fan, MS; Tim Peoples, MA; Jenifer Levinson; and Scott W. Lee, MD
A major challenge of managing type 2 diabetes mellitus (T2D) is the escalation of therapies in the response to treatment regimen failure. Indeed, this treatment escalation is now the standard of care for this disease. Antidiabetic drugs are added to therapy regimens if hyperglycemia and elevated glycosylated hemoglobin (A1C) values persist after the first stage of lifestyle and pharmacologic interventions.1 Intensive insulin therapy is often not added until multiple antidiabetic drugs fail to maintain euglycemia. However, even with the addition of insulin, many patients continue using multiple antidiabetic drugs. Moreover, as the disease progresses, patients with T2D have increased healthcare resource utilization, including emergency department (ED) visits and inpatient admissions for diabetesrelated complications and comorbidities.2-4 Insulin pump therapy, also called continuous subcutaneous insulin infusion (CSII), is not usually initiated in most T2D treatment regimens until multiple daily injection (MDI) therapy has failed. A few studies5-9 have examined whether switching from antidiabetic drugs or conventional insulin therapy to CSII offers a clinical benefit over switching to MDI. Such studies have focused on change in A1C level and have had mixed results. These studies did not examine whether CSII reduces utilization of antidiabetic drugs or other healthcare resources.
A plausible area for investigation drawn from the sparse literature about CSII in T2D is whether switching to this therapy after MDI has failed can reduce the number of antidiabetic drugs used and the amount of healthcare resource utilization needed to manage the disease. The present study investigates antidiabetic drug and healthcare resource utilization among a large real-world population of patients with T2D who switched from MDI to CSII.
This study was a claims analysis using medical, pharmacy, enrollment, and laboratory data to assess the effects of switching from MDI to CSII. Subjects were enrollees in a large geographically diverse US managed care health plan with documentation of T2D. No identifiable protected health information was extracted or accessed during the course of the study. Pursuant to the Health Insurance Portability and Accountability Act of 1996,10 the use of deidenti-fied data does not require institutional review board approval or waiver of authorization. Clinical outcomes (change in A1C levels and A1C targets) of this population are published separately.11
Medical claims or encounter data were collected from all available points of service such as inpatient and outpatient hospital records, ED visits, physician’s office encounters, and surgery center data, including specialty, preventive, and office-based treatments. Medical claims and coding conformed to insurance industry standards. Included in the database were pharmacy claims representing all prescriptions filled at outpatient pharmacies and submitted to the insurance plan for reimbursement. A 12-month period before CSII initiation was used to examine baseline demographic and clinical characteristics. The follow-up period was a minimum of 6 months and a maximum of 40 months. Baseline and follow-up periods were measured from the date of CSII initiation. Data from January 1, 1998, through April 30, 2008, were included in the study.
Patients were included if they initiated CSII during the subject identification period (January 1, 2005, through October 31, 2007) and had evidence of T2D. Evidence of T2D was determined by the presence of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes for T2D (a fifth digit of 0 or 2) in the medical record or by the use of any oral antidiabetic drug or exenatide in the claims history. Exclusion criteria included age younger than 18 years, missing information on sex, evidence of CSII use during the baseline period, lack of continuous enrollment in the health plan for a 12-month baseline period or less than a 6-month follow-up period, and type 1 diabetes mellitus–related ICD-9-CM codes without evidence of oral antidiabetic drug or exenatide use.
Claims were analyzed at the baseline period and after CSII initiation for changes in antidiabetic drug (defined as any oral antidiabetic drug or exenatide) and healthcare resource utilization. Change in antidiabetic drug utilization was calculated as the number of antidiabetic drugs used after CSII initiation minus the number of antidiabetic drugs used during the baseline period. Healthcare resource utilization was calculated as the rate of ED visits, inpatient admissions, and ambulatory visits per subject per month (PSPM) during the baseline period and after CSII initiation. The number of ambulatory visits represented all visits for outpatient services that generated costs for care and not just physician office visits for the care and management of diabetes.
All study variables were analyzed descriptively. Numbers and percentages were provided for dichotomous and polychotomous variables. Means, medians, standard deviations,and percentiles were calculated for continuous variables. Univariate analysis using paired t test was performed on the changes in antidiabetic drug and healthcare resource utilization. P <.05 was considered statistically significant.
Antidiabetic Drug Utilization
Of 3649 enrollees identified as having T2D and using CSII, 943 met criteria for inclusion in the study (Figure 1). Their mean age was 48 years, and they were followed up for a mean of 17 months (range, 6-39 months) (Table 1). Commonly reported comorbid conditions included lipid metabolism disorders, hypertension, and diseases of the heart, thyroid, and eye.
The mean (SD) number of antidiabetic drugs used per subject decreased from 1.45 (1.16) during the baseline period to 0.78 (1.01) after CSII initiation (a change of 46%, P<.001), which represented a mean (SD) reduction in antidiabetic drug utilization of 0.67 (1.26) (P < .001). Among 4 commonly used antidiabetic drugs (exenatide, metformin, sulfonylurea, and thiazolidine-dione), the reductions in utilization after CSII initiation ranged from 27% to 59% (Table 2).
There was a statistically significant increase in the number of subjects taking zero antidiabetic drugs and a statistically significant decrease in the number of subjects taking 2 or 3 or more antidiabetic drugs (Figure 2). The number of subjects using multiple antidiabetic drugs decreased from 380 (40%) during the baseline period to 161 (17%) after CSII initiation, a statistically significant reduction of 58% (P <.001). More than onethird of subjects (270 of 755 [36%]) taking antidiabetic drugs during the baseline period discontinued antidiabetic drugs after CSII initiation.
Significantly fewer subjects added antidiabetic drugs to their therapy regimen after CSII initiation (236 subjects [25%]) than during the baseline period (396 subjects [42%]) (P <.001). More subjects discontinued and switched antidiabetic drugs after CSII initiation than during the baseline period, but the difference was not statistically significant (62 [7%] to 82 [9%] for discontinuation [P = .09]; 21 [2%] to 12 [1%] for switching [P = .12]).
Healthcare Resource Utilization
From the baseline period to after CSII initiation, there was a statistically significant decrease in ED visits and inpatient admissions (0.03 PSPM [P = .001] and 0.02 PSPM [P <.001], respectively) and a statistically significant increase in ambulatory visits (0.21 PSPM [P <.001]). When the change in PSPM rate was projected over 4 years, the resultant healthcare resource utilization was 1.4 fewer ED visits and 1 fewer inpatient admission by using CSII rather than MDI. When the change in PSPM rate was projected over 1 year, the result was 0.4 less ED visit and 0.2 less inpatient admission (Table 3).
PDF is available on the last page.